Full Press Release Details
We have developed and validated the Nu.Q® H3K27Me3 immunoassay , an automated blood-based assay for quantifying circulating H3K27Me3-nucleosomes—key biomarkers of EZH2 and PRC2 inhibitor activity.
By normalizing results with our Nu.Q® H3.1 assay, we enable accurate, non-invasive monitoring of epigenetic drug efficacy in both cellular and animal models. This platform supports real-time assessment during preclinical and clinical development, offering a powerful tool for advancing targeted cancer therapies.
Learn more about Nu.Q® Discover
Related Articles
• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
Data Showing the Prognostic Value of its Nu.Q® Cancer Test
Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields